Ruwanthi N. Gunawardane, Ph.D.

Area:
Cell biology
Google:
"Ruwanthi Gunawardane"
Mean distance: 18.83 (cluster 46)
 

Parents

Sign in to add mentor
Yixian Zheng grad student 2002 Johns Hopkins
 (Biochemical and functional analysis of the Drosophila gammaTuRC proteins.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Gunawardane RN, Fordstrom P, Piper DE, et al. (2015) Agonistic Human Antibodies Binding To Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism. The Journal of Biological Chemistry
Piper DE, Romanow WG, Gunawardane RN, et al. (2015) The high resolution crystal structure of human LCAT. Journal of Lipid Research
Gunawardane RN, Nepomuceno RR, Rooks AM, et al. (2013) Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells. Molecular Cancer Therapeutics. 12: 438-47
Liu G, Abraham S, Tran L, et al. (2012) Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index. Journal of Medicinal Chemistry. 55: 3250-60
James J, Ruggeri B, Armstrong RC, et al. (2012) CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Molecular Cancer Therapeutics. 11: 930-41
Rowbottom MW, Faraoni R, Chao Q, et al. (2012) Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. Journal of Medicinal Chemistry. 55: 1082-105
Holladay MW, Campbell BT, Rowbottom MW, et al. (2011) 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors. Bioorganic & Medicinal Chemistry Letters. 21: 5342-6
Wolfer A, Wittner BS, Irimia D, et al. (2010) MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proceedings of the National Academy of Sciences of the United States of America. 107: 3698-703
Chao Q, Sprankle KG, Grotzfeld RM, et al. (2009) Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Journal of Medicinal Chemistry. 52: 7808-16
Zarrinkar PP, Gunawardane RN, Cramer MD, et al. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 114: 2984-92
See more...